Td Asset Management Inc Novavax Inc Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$36.28 - $75.29 $185,572 - $385,108	-5,115 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$69.73 - $142.9 $1.13 Million - $2.32 Million	-16,268 Reduced 76.08%	5,115 $377,000
Q4 2021 Feb 10, 2022	SELL	$134.56 - $217.97 $2.03 Million - $3.29 Million	-15,107 Reduced 41.4%	21,383 $3.06 Million
Q3 2021 Nov 09, 2021	BUY	$177.8 - $270.58 $1.23 Million - $1.88 Million	6,930 Added 23.44%	36,490 $7.57 Million
Q2 2021 Aug 11, 2021	BUY	$121.0 - $257.67 $555,632 - $1.18 Million	4,592 Added 18.39%	29,560 $5.3 Million
Q1 2021 May 14, 2021	BUY	$112.98 - $319.93 $662,966 - $1.88 Million	5,868 Added 30.72%	24,968 $4.53 Million
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $669,290 - $1.19 Million	8,500 Added 80.19%	19,100 $2.13 Million
Q3 2020 Nov 10, 2020	SELL	$79.44 - $178.51 $111,216 - $249,914	-1,400 Reduced 11.67%	10,600 $1.15 Million
Q2 2020 Aug 13, 2020	BUY	$13.86 - $83.61 $166,320 - $1 Million	12,000 New	12,000 $1 Million

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $704M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.